Plasmalogens, platelet-activating factor, and other ether glycerophospholipids

Bioactive Lipids

Volumn , Issue , 2012, Pages 107-134

  Farooqui, Akhlaq A ^a   Horrocks, Lloyd A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646551287     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1533/9780857097934.107     Document Type: Chapter

References (144)

1. Adachi T., Aoki J., Manya H., Asou H., Arai H., Inoue K. PAF analogues capable of inhibiting PAF acetylhydrolase activity suppress migration of isolated rat cerebellar granule cells. Neurosci Lett 1997, 235:133-136.
2. Albert C.J., Crowley J.R., Hsu F.F., Thukkani A.K., Ford D.A. Reactive brominating species produced by myeloperoxidase target the vinyl ether bond of plasmalogens - Disparate utilization of sodium halides in the production of alpha-halo fatty aldehydes. J Biol Chem 2002, 277:4694-4703.
3. 2 in nuclei of LA-N-1 neuroblastoma cells. Neurochem Res 2001, 26:83-88.
4. 2 and production of arachidonic acid in nuclei of LA-N-1 cell cultures: a specific receptor activation mediated with retinoic acid. Mol Brain Res 2003, 115:187-195.
5. Arai H. Platelet-activating factor acetylhydrolase. Prostaglandins Other Lipid Mediat 2002, 68-69:83-94.
6. Arditi M., Manogue K.R., Caplan M., Yogev R. Cerebrospinal fluid cachectin/tumor necrosis factor-α and platelet-activating factor concentrations and severity of bacterial meningitis in children. J Infect Dis 1990, 162:139-147.
7. Arthur G., Bittman R. The inhibition of cell signaling pathways by antitumor ether lipids. Biochim Biophys Acta Lipids Lipid Metab 1998, 1390:85-102.
8. Bazan N.G., Fletcher B.S., Herschman H.R., Mukherjee P.K. Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene. Proc Natl Acad Sci USA 1994, 91:5252-5256.
9. Bazan N.G., Packard M.G., Teather L., Allan G. Bioactive lipids in excitatory neurotransmission and neuronal plasticity. Neurochem Int 1997, 30:225-231.
10. Berggren M.I., Gallegos A., Dressler L.A., Modest E.J., Powis G. Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues. Cancer Res 1993, 53:4297-4302.
11. Berkovic D. Cytotoxic etherphospholipid analogues. Gen Pharmacol 1998, 31:511-517.
12. 2 in human leukemia cells by the etherphospholipid analogue hexadecylphosphocholine. Biochem Pharmacol 1997, 53:1725-1733.
13. Bichenkov E., Ellingson J.S. Temporal and quantitative expression of the myelin-associated lipids, ethanolamine plasmalogen, galactocerebroside, and sulfatide, in the differentiating CG-4 glial cell line. Neurochem Res 1999, 24:1549-1556.
14. Bix G.J., Clark G.D. Platelet-activating factor receptor stimulation disrupts neuronal migration in vitro. J Neurosci 1998, 18:307-318.
15. Bjerrum O.W., Nielsen H., Borregaard N. Quantitative analysis of phospholipids and demonstration of plasmalogen in human neutrophil subcellular fractions by high-performance liquid chromatography. Scand J Clin Lab Invest 1989, 49:613-622.
16. Blank M.L., Smith Z.L., Fitzgerald V., Snyder F. The CoA-independent transacylase in PAF biosynthesis: Tissue distribution and molecular species selectivity. Biochim Biophys Acta Lipids Lipid Metab 1995, 1254:295-301.
17. Breckenridge W.C., Morgan I.G., Zanetta J.P., Vincendon G. Adult rat brain synaptic vesicles. II. Lipid composition. Biochim Biophys Acta 1973, 320:681-686.
18. Brochet B., Guinot P., Orgogozo J.M., Confavreux C., Rumbach L., Lavergne V., Ginkgolide Study Group in MS Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. J Neurol Neurosurg Psychiatry 1995, 58:360-362.
19. Brosche T., Platt D., Knopf B. Decreased concentrations of serum phospholipid plasmalogens indicate oxidative burden of uraemic patients undergoing haemodialysis. Nephron 2002, 90:58-63.
20. Brosius U., Gartner J. Cellular and molecular aspects of Zellweger syndrome and other peroxisome biogenesis disorders. Cell Mol Life Sci 2002, 59:1058-1069.
21. Brunnemann S.R., Segal J.L. Amikacin serum protein binding in spinal cord injury. Life Sci 1991, 49:PL1-PL5.
22. Cabellos C., MacIntyre D.E., Forrest M., Burroughs M., Prasad S., Tuomanen E. Differing roles for platelet-activating factor during inflammation of the lung and subarachnoid space. The special case of. Streptococcus pneumoniae. J Clin Invest 1992, 90:612-618.
23. Callea L., Arese M., Orlandini A., Bargnani C., Priori A., Bussolino F. Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 1999, 94:212-221.
24. Carballeira N.M. New advances in the chemistry of methoxylated lipids. Prog Lipid Res 2002, 41:437-456.
25. Catalán R.E., Martínez A.M., Aragonés M.D., Garde E., Díaz G. Platelet-activating factor stimulates protein kinase C translocation in cerebral microvessels. Biochem Biophys Res Commun 1993, 192:446-451.
26. Chao W., Olson M.S. Platelet-activating factor: Receptors and signal transduction. Biochem J 1993, 292:617-629.
27. Cross G.A.M. Glycolipid anchoring of plasma membrane proteins. Annu Rev Cell Biol 1990, 6:1-39.
28. del Cerro S., Arai A., Lynch G. Inhibition of long-term potentiation by an antagonist of platelet-activating factor receptors. Behav Neural Biol 1990, 54:213-217.
29. Demediuk P., Saunders R.D., Anderson D.K., Means E.D., Horrocks L.A. Membrane lipid changes in laminectomized and traumatized cat spinal cord. Proc Natl Acad Sci USA 1985, 82:7071-7075.
30. Derewenda Z.S., Derewenda U. The structure and function of platelet-activating factor acetylhydrolases. Cell Mol Life Sci 1998, 54:446-455.
31. Duhm J., Engelmann B., Schönthier U.M., Streich S. Accelerated maximal velocity of the red blood cell Na+/K+ pump in hyperlipidemia is related to increase in 1-palmitoyl-2-arachidonoyl-plasmalogen phosphatidylethanolamine. Biochim Biophys Acta Bio-Membr 1993, 1149:185-188.
32. Engelmann B., Streich S., Schönthier U.M., Richter W.O., Duhm J. Changes of membrane phospholipid composition of human erythrocytes in hyperlipidemias. I. Increased phosphatidylcholine and reduced sphingomyelin in patients with elevated levels of triacylglycerol-rich lipoproteins. Biochim Biophys Acta Lipids Lipid Metab 1992, 1165:32-37.
33. Engelmann B., Bräutigam C., Thiery J. Plasmalogen phospholipids as potential protectors against lipid peroxidation of low density lipoproteins. Biochem Biophys Res Commun 1994, 204:1235-1242.
34. Faden A.I., Halt P. Platelet-activating factor reduces spinal cord blood flow and causes behavioral deficits after intrathecal administration in rats through a specific receptor mechanism. J Pharmacol Exp Ther 1992, 261:1064-1070.
35. Farooqui A.A., Horrocks L.A. Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist 2001, 7:232-245.
36. 2, and signal transduction. Brain Res Rev 1995, 21:152-161.
37. Farooqui A.A., Rapoport S.I., Horrocks L.A. Membrane phospholipid alterations in Alzheimer disease: Deficiency of ethanolamine plasmalogens. Neurochem Res 1997, 22:523-527.
38. Farooqui A.A., Horrocks L.A., Farooqui T. Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem Phys Lipids 2000, 106:1-29.
39. Ford D.A., Gross R.W. Identification of endogenous 1-O-alk-1'-enyl-2-acyl-sn-glycerol in myocardium and its effective utilization by choline phosphotransferase. J Biol Chem 1988, 263:2644-2650.
40. Ford D.A., Gross R.W. Differential accumulation of diacyl and plasmalogenic diglycerides during myocardial ischemia. Circ Res 1989, 64:173-177.
41. Ford D.A., Hale C.C. Plasmalogen and anionic phospholipid dependence of the cardiac sarcolemmal sodium-calcium exchanger. FEBS Lett 1996, 394:99-102.
42. Ford D.A., Miyake R., Glaser P.E., Gross R.W. Activation of protein kinase C by naturally occurring ether-linked diglycerides. J Biol Chem 1989, 264:13818-13824.
43. Francescangeli E., Domanska-Janik K., Goracci G. Relative contribution of the de novo and remodelling pathways to the synthesis of platelet-activating factor in brain areas and during ischemia. J Lipid Mediat Cell Signal 1996, 14:89-98.
44. Gelbard H.A., Nottet H.S.L.M., Swindells S., Jett M., Dzenko K.A., Genis P., White R., Wang L., Choi Y.-B., Zhang D., Lipton S.A., Tourtellotte W.W., Epstein L.G., Gendelman H.E. Platelet-activating factor: A candidate human immunodeficiency virus type 1-induced neurotoxin. J Virol 1994, 68:4628-4635.
45. Ginsberg L., Rafique S., Xuereb J.H., Rapoport S.I., Gershfeld N.L. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Brain Res 1995, 698:223-226.
46. Ginsberg L., Xuereb J.H., Gershfeld N.L. Membrane instability, plasmalogen content, and Alzheimer's disease. J Neurochem 1998, 70:2533-2538.
47. Goracci G., Francescangeli E., Dreyfus H., Boila A., Freysz L. The synthesis of platelet-activating factor in brain and neural cells. J Lipid Mediat 1994, 10:7-8.
48. Gross R.W. Identification of plasmalogen as the major phospholipid constituent of cardiac sarcoplasmic reticulum. Biochemistry 1985, 24:1662-1668.
49. Guan Z.Z., Wang Y.A., Cairns N.J., Lantos P.L., Dallner G., Sindelar P.J. Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol 1999, 58:740-747.
50. Han X.L., Holtzman D.M., McKeel D.W. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem 2001, 77:1168-1180.
51. Hashimoto K., Hirasawa R., Makino S. Comparison of the effects of intra-third ventricular administration of interleukin-1 or platelet activating factor on ACTH secretion and the sympathetic-adrenomedullary system in conscious rats. Acta Med Okayama 1993, 47:1-6.
52. Hattori M., Adachi H., Tsujimoto M., Arai H., Inoue K. Miller-Dieker lissencephaly gene encodes a subunit of brain platelet-activating factor acetylhydrolase. Nature 1994, 370:216-218.
53. 2. Implications for the coordinated regulation of phospholipolysis and glycolysis. J Biol Chem 1993, 268:9892-9900.
54. 2 during rabbit myocardial ischemia which is highly selective for plasmalogen substrate. J Biol Chem 1991, 266:5629-5633.
55. Heymans H.S.A., Schutgens R.B.H., Tan R., van den Bosch H., Borst P. Severe plasmalogen deficiency in tissues of infants without peroxisomes (Zellweger syndrome). Nature 1983, 306:69-70.
56. 2 from bovine brain cytosol. J Neurochem 1992, 59:708-714.
57. Honda Z., Ishii S., Shimizu T. Platelet-activating factor receptor. J Biochem 2002, 131:773-779.
58. Honer W.G., Falkai P., Chen C., Arango V., Mann J.J., Dwork A.J. Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness. Neuroscience 1999, 91:1247-1255.
59. Hong S., Gronert K., Devchand P.R., Moussignac R.L., Serhan C.N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells - Autacoids in anti-inflammation. J Biol Chem 2003, 278:14677-14687.
60. Horrocks L.A. Composition of myelin from peripheral and central nervous systems of the squirrel monkey. J Lipid Res 1967, 8:569-576.
61. Horrocks L.A. Ether Lipids: Chemistry and Biology. Content, composition, and metabolism of mammalian and avian lipids that contain ether groups 1972, 177-272. Academic Press, New York. F. Snyder (Ed.).
62. Horrocks L.A. Sources of brain arachidonic acid uptake and turnover in glycerophospholipids. Ann N Y Acad Sci 1989, 559:17-24.
63. Horrocks L.A., Yeo Y.K., Harder H.W., Mozzi R., Goracci G. Choline plasmalogens, glycerophospholipid methylation, and receptor-mediated activation of adenylate cyclase. Advances in Cyclic Nucleotide and Protein Phosphorylation Research 1986, 20:263-292. Raven Press, New York. P. Greengard, G.A. Robison (Eds.).
64. Hunyadi J., Kenderessy A.S., Duda E., Braquet P., Dobozy A. Platelet-activating factor antagonists (BN 52021 and BN 50730) inhibit tumor necrosis factor-α-mediated cytotoxicity on murine L929 tumor cells. Mol Immunol 1993, 30:517-519.
65. Ishii S., Shimizu T. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res 2000, 39:41-82.
66. Ishii S., Nagase T., Tashiro F., Ikuta K., Sato S., Waga I., Kume K., Miyazaki J., Shimizu T. Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor. EMBO J 1997, 16:133-142.
67. Ishii S., Kuwaki T., Nagase T., Maki K., Tashiro F., Sunaga S., Cao W.H., Kume K., Fukuchi Y., Ikuta K., Miyazaki J., Kumada M., Shimizu T. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J Exp Med 1998, 187:1779-1788.
68. Ishii S., Nagase T., Shimizu T. Platelet-activating factor receptor. Prostaglandins Other Lipid Mediat 2002, 68-9:599-609.
69. Izumi T., Shimizu T. Platelet-activating factor receptor: Gene expression and signal transduction. Biochim Biophys Acta Lipids Lipid Metab 1995, 1259:317-333.
70. 2 in cytosol of small intestinal epithelium. Biochim Biophys Acta Lipids Lipid Metab 1999, 1437:142-156.
71. Kato K., Zorumski C.F. Platelet-activating factor as a potential retrograde messenger. J Lipid Mediat Cell Signal 1996, 14:341-348.
72. Kato K., Clark G.D., Bazan N.G., Zorumski C.F. Platelet-activating factor as a potential retrograde messenger in CA1 hippocampal long-term potentiation. Nature 1994, 367:175-179.
73. Kochanek P.M., Nemoto E.M., Melick J.A., Evans R.W., Burke D.F. Cerebrovascular and cerebrometabolic effects of intracarotid infused platelet-activating factor in rats. J Cereb Blood Flow Metab 1988, 8:546-551.
74. Kochanek P.M., Melick J.A., Schoettle R.J., Magargee M.J., Evans R.W., Nemoto E.M. Endogenous platelet activating factor does not modulate blood flow and metabolism in normal rat brain. Stroke 1990, 21:459-462.
75. Koizumi K., Shimizu S., Koizumi K.T., Nishida K., Sato C., Ota K., Yamanaka N. Rapid isolation and lipid characterization of plasma membranes from normal and malignant lymphoid cells of mouse. Biochim Biophys Acta 1981, 649:393-403.
76. Kornecki E., Wieraszko A., Chan J.C., Ehrlich Y.H. Platelet activating factor (PAF) in memory formation: Role as a retrograde messenger in long-term potentiation. J Lipid Mediat Cell Signal 1996, 14:115-126.
77. Latorre E., Aragonés M.D., Fernández I., Catalán R.E. Platelet-activating factor modulates brain sphingomyelin metabolism. Eur J Biochem 1999, 262:308-314.
78. Latorre E., Collado M.P., Fernández I., Aragonés M.D., Catalán R.E. Signaling events mediating activation of brain ethanolamine plasmalogen hydrolysis by ceramide. Eur J Biochem 2003, 270:36-46.
79. Lee T.C. Biosynthesis and possible biological functions of plasmalogens. Biochim Biophys Acta Lipids Lipid Metab 1998, 1394:129-145.
80. Liliom K., Fischer D.J., Virág T., Sun G., Miller D.D., Tseng J.L., Desiderio D.M., Seidel M.C., Erickson J.R., Tigyi G. Identification of a novel growth factor-like lipid, 1-O-cis-alk-1'-enyl-2-lyso-sn-glycero-3-phosphate (alkenyl-GP) that is present in commercial sphingolipid preparations. J Biol Chem 1998, 273:13461-13468.
81. Liliom K., Guan Z., Tseng J.L., Desiderio D.M., Tigyi G., Watsky M.A. Growth factor-like phospholipids generated after corneal injury. Am J Physiol 1998, 274:C1065-C1074.
82. Lindsberg P.J., Jacobs T.P., Paakkari I.A., Hallenbeck J.M., Feuerstein G. Effect of systemic platelet-activating factor (PAF) on the rabbit spinal cord microcirculation. J Lipid Mediat 1990, 2:41-58.
83. Lindsberg P.J., Hallenbeck J.M., Feuerstein G. Platelet-activating factor in stroke and brain injury. Ann Neurol 1991, 30:117-129.
84. Liu S.J., McHowat J., Creer M.H. Effects of lysoplasmenylcholine on membrane currents in rabbit ventricular myocytes. J Mol Cell Cardiol 1999, 31:27. [Abstract].
85. Lohner K. Is the high propensity of ethanolamine plasmalogens to form non-lamellar lipid structures manifested in the properties of biomembranes?. Chem Phys Lipids 1996, 81:167-184.
86. Lukacova N., Halat G., Chavko M., Marsala J. Ischemia-reperfusion injury in the spinal cord of rabbits strongly enhances lipid peroxidation and modifies phospholipid profiles. Neurochem Res 1996, 21:869-873.
87. Maclennan K.M., Smith P.F., Darlington C.L. Platelet-activating factor in the CNS. Prog Neurobiol 1996, 50:585-596.
88. Maeba R., Ueta N. Ethanolamine plasmalogens prevent the oxidation of cholesterol by reducing the oxidizability of cholesterol in phospholipid bilayers. J Lipid Res 2003, 44:164-171.
89. Mandel H., Sharf R., Berant M., Wanders R.J.A., Vreken P., Aviram M. Plasmalogen phospholipids are involved in HDL-mediated cholesterol efflux: Insights from investigations with plasmalogen-deficient cells. Biochem Biophys Res Commun 1998, 250:369-373.
90. Marcheselli V.L., Bazan N.G. Platelet-activating factor is a messenger in the electroconvulsive shock-induced transcriptional activation of c-fos and zif-268 in hippocampus. J Neurosci Res 1994, 37:54-61.
91. Marcheselli V.L., Hong S., Lukiw W.J., Tian X.H., Gronert K., Musto A., Hardy M., Gimenez J.M., Chiang N., Serhan C.N., Bazan N.G. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 2003, 278:43807-43817.
92. Martin M., Serradji N., Dereuddre-Bosquet N., Le Pavec G., Fichet G., Lamouri A., Heymans F., Godfroid J.J., Clayette P., Dormont D. PMS-601, a new platelet-activating factor receptor antagonist that inhibits human immunodeficiency virus replication and potentiates zidovudine activity in macrophages. Antimicrob Agents Chemother 2000, 44:3150-3154.
93. 2 and conservation of plasmalogen polyunsaturated fatty acids in diabetic heart. Am J Physiol Endocrinol Metab 2000, 279:E25-E32.
94. Mollinedo F., Gajate C., Modolell M. The ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine induces expression of fos and jun proto-oncogenes and activates AP-1 transcription factor in human leukaemic cells. Biochem J 1994, 302:325-329.
95. Mueller H.W., Haught C.A., McNatt J.M., Cui K., Gaskell S.J., Johnston D.A., Willerson J.T. Measurement of platelet-activating factor in a canine model of coronary thrombosis and in endarterectomy samples from patients with advanced coronary artery disease. Circ Res 1995, 77:54-63.
96. Müller E., Dagenais P., Alami N., Rola-Pleszczynski M. Identification and functional characterization of platelet-activating factor receptors in human leukocyte populations using polyclonal anti-peptide antibody. Proc Natl Acad Sci USA 1993, 90:5818-5822.
97. Munn N.J., Arnio E., Liu D., Zoeller R.A., Liscum L. Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. J Lipid Res 2003, 44:182-192.
98. Murphy E.J., Schapiro M.B., Rapoport S.I., Shetty H.U. Phospholipid composition and levels are altered in Down syndrome brain. Brain Res 2000, 867:9-18.
99. Murphy R.C. Free-radical-induced oxidation of arachidonoyl plasmalogen phospholipids: Antioxidant mechanism and precursor pathway for bioactive eicosanoids. Chem Res Toxicol 2001, 14:463-472.
100. Nagan N., Zoeller R.A. Plasmalogens: biosynthesis and functions. Prog Lipid Res 2001, 40:199-229.
101. Nagase T., Ishii S., Katayama H., Fukuchi Y., Ouchi Y., Shimizu T. Airway responsiveness in transgenic mice overexpressing platelet-activating factor receptor. Roles of thromboxanes and leukotrienes. Am J Respir Crit Care Med 1997, 156:1621-1627.
102. Nagase T., Ishii S., Kume K., Uozumi N., Izumi T., Ouchi Y., Shimizu T. Platelet-activating factor mediates acid-induced lung injury in genetically engineered mice. J Clin Invest 1999, 104:1071-1076.
103. Noris M., Benigni A., Boccardo P., Gotti E., Benfenati E., Aiello S., Todeschini M., Remuzzi G. Urinary excretion of platelet activating factor in patients with immune-mediated glomerulonephritis. Kidney Int 1993, 43:426-429.
104. Oken R.J., Schulzer M. At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophr Bull 1999, 25:625-638.
105. Packard M.G., Teather L.A., Bazan N.G. Effects of intrastriatal injections of platelet-activating factor and the PAF antagonist BN 52021 on memory. Neurobiol Learn Mem 1996, 66:176-182.
106. Paltauf F. Ether lipids in biomembranes. Chem Phys Lipids 1994, 74:101-139.
107. Périchon R., Moser A.B., Wallace W.C., Cunningham S.C., Roth G.S., Moser H.W. Peroxisomal disease cell lines with cellular plasmalogen deficiency have impaired muscarinic cholinergic signal transduction activity and amyloid precursor protein secretion. Biochem Biophys Res Commun 1998, 248:57-61.
108. Pettegrew J.W., Panchalingam K., Hamilton R.L., McClure R.J. Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 2001, 26:771-782.
109. 2 from rabbit kidney. J Biol Chem 1996, 271:15451-15457.
110. 2 in hypoxic injury to rabbit proximal tubules. J Clin Invest 1994, 93:1609-1615.
111. Powis G., Seewald M.J., Gratas C., Melder D., Riebow J., Modest E.J. Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. Cancer Res 1992, 52:2835-2840.
112. Prescott S.M., Zimmerman G.A., McIntyre T.M. Platelet-activating factor. J Biol Chem 1990, 265:17381-17384.
113. 2 with high specificity for oxidized phospholipids and platelet activating factor. Biochem J 1998, 330:1309-1315.
114. 2 is a target for chronic lithium in rat brain. NeuroReport 1999, 10:3887-3890.
115. Roberts W.L., Myher J.J., Kuksis A., Rosenberry T.L. Alkylacylglycerol molecular species in the glycosylinositol phospholipid membrane anchor of bovine erythrocyte acetylcholinesterase. Biochem Biophys Res Commun 1988, 150:271-277.
116. Rougeot C., Junier M.P., Minary P., Weidenfeld J., Braquet P., Dray F. Intracerebroventricular injection of platelet-activating factor induces secretion of adrenocorticotropin, beta-endorphin and corticosterone in conscious rats: a possible link between the immune and nervous systems. Neuroendocrinology 1990, 51:267-275.
117. Rüdiger M., Kolleck I., Putz G., Wauer R.R., Stevens P., Rüstow B. Plasmalogens effectively reduce the surface tension of surfactant-like phospholipid mixtures. Am J Physiol Lung Cell Mol Physiol 1998, 274:L143-L148.
118. Rüdiger M., von Baehr A., Haupt R., Wauer R.R., Rüstow B. Preterm infants with high polyunsaturated fatty acid and plasmalogen content in tracheal aspirates develop bronchopulmonary dysplasia less often. Crit Care Med 2000, 28:1572-1577.
119. Sasaki Y., Asaoka Y., Nishizuka Y. Potentiation of diacylglycerol-induced activation of protein kinase C by lysophospholipids. FEBS Lett 1993, 320:47-51.
120. Schedin S., Sindelar P.J., Pentchev P., Brunk U., Dallner G. Peroxisomal impairment in Niemann-Pick type C disease. J Biol Chem 1997, 272:6245-6251.
121. Schulman G., Bodine P.V., Litwack G. Modulators of the glucocorticoid receptor also regulate mineralocorticoid receptor function. Biochemistry 1992, 31:1734-1741.
122. Serhan C.N., Hong S., Gronert K., Colgan S.P., Devchand P.R., Mirick G., Moussignac R.L. Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002, 196:1025-1037.
123. Snyder F. Platelet-activating factor: the biosynthetic and catabolic enzymes. Biochem J 1995, 305:689-705.
124. Snyder F., Lee T.-C., Wykle R.L. Ether-linked glycerolipids and their bioactive species: Enzymes and metabolic regulation. The Enzymes of Biological Membranes 1985, 1-58. Plenum Publishing Corp, New York. A.N. Martonosi (Ed.).
125. Stafforini D.M., Prescott S.M., Zimmerman G.A., McIntyre T.M. Mammalian platelet-activating factor acetylhydrolases. Biochim Biophys Acta 1996, 1301:161-173.
126. Stenvinkel P., Holmberg I., Heimburger O., Diczfalusy U. A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients. Nephrol Dial Transplant 1998, 13:2594-2600.
127. Thakur A., Willcox M.D. Cytokine and lipid inflammatory mediator profile of human tears during contact lens associated inflammatory diseases. Exp Eye Res 1998, 67:9-19.
128. Tjoelker L.W., Stafforini D.M. Platelet-activating factor acetylhydrolases in health and disease. Biochim Biophys Acta 2000, 1488:102-123.
129. Tsukioka K., Matsuzaki M., Nakamata M., Kayahara H., Nakagawa T. Increased plasma level of platelet-activating factor (PAF) and decreased serum PAF acetylhydrolase (PAFAH) activity in adults with bronchial asthma. J Investig Allergol Clin Immunol 1996, 6:22-29.
130. 2 receptor in U46619-stimulated human platelets. Biochim Biophys Acta Lipids Lipid Metab 1994, 1213:21-26.
131. Unger C., Maniera T., Kaufmann-Kolle P., Eibl H. In vivo antileishmanial activity of hexadecylphosphocholine and other alkylphosphocholines. Drugs Today 1998, 34(Suppl. F):133-140.
132. van der Luit A.H., Budde M., Ruurs P., Verheij M., Van Blitterswijk W.J. Alkyllysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J Biol Chem 2002, 277:39541-39547.
133. Walsh C.A. LISsen up!. Nature Genet 1998, 19:307-308.
134. Watkins L.R., Milligan E.D., Maier S.F. Glial activation: a driving force for pathological pain. Trends Neurosci 2001, 24:450-455.
135. Wells K., Farooqui A.A., Liss L., Horrocks L.A. Neural membrane phospholipids in Alzheimer disease. Neurochem Res 1995, 20:1329-1333.
136. Williams S.D., Ford D.A. Activation of myocardial cAMP-dependent protein kinase by lysoplasmenylcholine. FEBS Lett 1997, 420:33-38.
137. 2 mediates CREB phosphorylation and c-fos expression during ischemia. Am J Physiol Heart Circ Physiol 2001, 281:H168-H176.
138. Wu R., Lemne C., De Faire U., Frostegard J. Antibodies to platelet-activating factor are associated with borderline hypertension, early atherosclerosis and the metabolic syndrome. J Intern Med 1999, 246:389-397.
139. Yamaguchi S., Tomomatsu N., Komatsu H. Effect of Y-24180, a receptor antagonist to platelet-activating factor (PAF), on allergic cutaneous reactions in actively sensitized mice. Inflamm Res 2000, 49:584-590.
140. Yanagihara T., Cumings J.N. Alterations of phospholipids, particularly plasmalogens, in the demyelination of multiple sclerosis as compared with that of cerebral oedema. Brain 1969, 92:59-70.
141. Yue T.L., Gleason M.M., Gu J.L., Lysko P.G., Hallenbeck J., Feuerstein G. Platelet-activating factor (PAF) receptor-mediated calcium mobilization and phosphoinositide turnover in neurohybrid NG108-15 cells: studies with BN50739, a new PAF antagonist. J Pharmacol Exp Ther 1991, 257:374-381.
142. Zimmerman G.A., Elstad M.R., Lorant D.E., Mclntyre T.M., Prescott S.M., Topham M.K., Weyrich A.S., Whatley R.E. Platelet-activating factor (PAF): signalling and adhesion in cell-cell interactions. Adv Exp Med Biol 1996, 416:297-304.
143. Zoeller R.A., Morand O.H., Raetz C.R.H. A possible role for plasmalogens in protecting animal cells against photosensitized killing. J Biol Chem 1988, 263:11590-11596.
144. Zoeller R.A., Lake A.C., Nagan N., Gaposchkin D.P., Legner M.A., Lieberthal W. Plasmalogens as endogenous antioxidants: somatic cell mutants reveal the importance of the vinyl ether. Biochem J 1999, 338:769-776.